Literature DB >> 34697069

Parathyroid Carcinoma and Adenoma Co-existing in One Patient: Case Report and Comparative Proteomic Analysis.

Federica Ciregia1,2, Filomena Cetani1, Elena Pardi1, Alessio Soggiu3, Cristian Piras4, Lorenzo Zallocco5, Simona Borsari1, Maurizio Ronci6, Vanni Caruso7, Claudio Marcocci1, Maria Rosa Mazzoni5, Antonio Lucacchini1, Laura Giusti8.   

Abstract

BACKGROUND/AIM: The lack of specific parathyroid carcinoma (PC) biomarkers in clinical practice points out the importance of analyzing the proteomic signature of this cancer. We performed a comparative proteomic analysis of PC and parathyroid adenoma (PA) co-existing in the same patient. PATIENTS AND METHODS: PC and PA were taken from a 63-year-old patient. Using two-dimensional differential gel electrophoresis (2D-DIGE) coupled to mass spectrometry we examined the differences between PC and PA proteins. For validation, additional PC and PA samples were obtained from 10 patients. Western blot analysis was used to validate the difference of expression observed with 2D-DIGE analysis. Bioinfomatic analysis was performed using QIAGEN's Ingenuity Pathways Analysis (IPA) to determine the predominant canonical pathways and interaction networks involved.
RESULTS: Thirty-three differentially expressed proteins were identified in PC compared to PA. Among these, ubiquitin C-terminal hydrolase-L1 (UCH-L1) was highly overexpressed in PC. The result was confirmed by Western Blot analysis in additional PC samples.
CONCLUSION: Our comparative proteomic analysis of co-existing neoplasms allowed detecting specific and peculiar differences between PC and PA overcoming population biological variability. Copyright
© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  2D-DIGE; Parathyroid carcinoma; biomarkers; case report; parathyroid adenoma; proteomics

Mesh:

Year:  2021        PMID: 34697069      PMCID: PMC8569818          DOI: 10.21873/cgp.20297

Source DB:  PubMed          Journal:  Cancer Genomics Proteomics        ISSN: 1109-6535            Impact factor:   4.069


  51 in total

1.  Differential protein expression of lymph node metastases of papillary thyroid carcinoma harboring the BRAF mutation.

Authors:  Won Seo Park; Ki-Wook Chung; Min Sun Young; Seok-Ki Kim; You Jin Lee; Eun Kyung Lee
Journal:  Anticancer Res       Date:  2013-10       Impact factor: 2.480

2.  PGP9.5 as a marker for invasive colorectal cancer.

Authors:  Taiji Yamazaki; Kenji Hibi; Tsunenobu Takase; Ekmel Tezel; Hiroshi Nakayama; Yasushi Kasai; Katsuki Ito; Seiji Akiyama; Tetsuro Nagasaka; Akimasa Nakao
Journal:  Clin Cancer Res       Date:  2002-01       Impact factor: 12.531

3.  Arginine Methylation of MDH1 by CARM1 Inhibits Glutamine Metabolism and Suppresses Pancreatic Cancer.

Authors:  Yi-Ping Wang; Wei Zhou; Jian Wang; Xian Huang; Yong Zuo; Tian-Shi Wang; Xue Gao; Ying-Ying Xu; Shao-Wu Zou; Ying-Bin Liu; Jin-Ke Cheng; Qun-Ying Lei
Journal:  Mol Cell       Date:  2016-11-10       Impact factor: 17.970

4.  Six novel MEN1 gene mutations in sporadic parathyroid tumors.

Authors:  F Cetani; E Pardi; A Giovannetti; P Cerrai; S Borsari; E Vignali; A Picone; L Cianferotti; P Miccoli; A Pinchera; C Marcocci
Journal:  Hum Mutat       Date:  2000-11       Impact factor: 4.878

5.  Role of Histological Criteria and Immunohistochemical Markers in Predicting Risk of Malignancy in Parathyroid Neoplasms.

Authors:  Niraj Kumari; Nandita Chaudhary; Roma Pradhan; Amit Agarwal; Narendra Krishnani
Journal:  Endocr Pathol       Date:  2016-06       Impact factor: 3.943

6.  Proteomics of human breast ductal carcinoma in situ.

Authors:  Julia D Wulfkuhle; Dennis C Sgroi; Henry Krutzsch; Kelley McLean; Kelly McGarvey; Melodie Knowlton; She Chen; Hongjun Shu; Aysegul Sahin; Raffael Kurek; Diethelm Wallwiener; Maria J Merino; Emanuel F Petricoin; Yingming Zhao; Patricia S Steeg
Journal:  Cancer Res       Date:  2002-11-15       Impact factor: 12.701

Review 7.  Annexin A2 (ANX A2): An emerging biomarker and potential therapeutic target for aggressive cancers.

Authors:  Mahesh C Sharma
Journal:  Int J Cancer       Date:  2018-10-31       Impact factor: 7.396

8.  Negative parafibromin staining predicts malignant behavior in atypical parathyroid adenomas.

Authors:  Schelto Kruijff; Stan B Sidhu; Mark S Sywak; Anthony J Gill; Leigh W Delbridge
Journal:  Ann Surg Oncol       Date:  2013-10-01       Impact factor: 5.344

Review 9.  The dynamic and stress-adaptive signaling hub of 14-3-3: emerging mechanisms of regulation and context-dependent protein-protein interactions.

Authors:  K L Pennington; T Y Chan; M P Torres; J L Andersen
Journal:  Oncogene       Date:  2018-06-18       Impact factor: 9.867

10.  HSP60-regulated Mitochondrial Proteostasis and Protein Translation Promote Tumor Growth of Ovarian Cancer.

Authors:  Jianying Guo; Xiao Li; Wenhao Zhang; Yuling Chen; Songbiao Zhu; Liang Chen; Renhua Xu; Yang Lv; Di Wu; Mingzhou Guo; Xiaohui Liu; Weiguo Lu; Haiteng Deng
Journal:  Sci Rep       Date:  2019-09-02       Impact factor: 4.379

View more
  1 in total

Review 1.  Genetics and Epigenetics of Parathyroid Carcinoma.

Authors:  Francesca Marini; Francesca Giusti; Gaia Palmini; Giuliano Perigli; Roberto Santoro; Maria Luisa Brandi
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-24       Impact factor: 5.555

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.